Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Death In Audentes’ XLMTM Gene Therapy Trial

But Companies Remain 'Committed'

Executive Summary

Astellas subsidiary says it “remains committed” to on-hold program in high-need disease despite fatal events.

You may also be interested in...



Adverum Halts Phase II Gene Therapy Trial After Patient’s Vision Loss

Slated to begin a Phase III later this year of ADVM-022 in wet AMD, Adverum had to scuttle a Phase II study of the gene therapy in DME after a patient suffered ocular hypotension, panuveitis and vision loss in the treated eye.

AnGes Takes Gene Editor Emendo Into Fold For $258m

Japanese firm sees broad promise in already affiliated US bioventure’s platform tech that will help it become a more global player in genetic medicine.

Quick Listen: Scrip’s Five Must-Know Things

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Topics

Related Companies

UsernamePublicRestriction

Register

SC142828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel